RESEARCH AND DEVELOPMENT
43 CANCER CONTROL 2021
1. Kim, H. S.; Sung, Y.-J.; Paik, S., Cancer Cell Line Panels Empower Genomics-Based Discovery
of Precision Cancer Medicine. Yonsei Med J 2015, 56 (5), 1186-1198.
2. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A. A.; Kim, S.;
Wilson, C. J.; Lehár, J.; Kryukov, G. V.; Sonkin, D.; Reddy, A.; Liu, M.; Murray, L.; Berger,
M. F.; Monahan, J. E.; Morais, P.; Meltzer, J.; Korejwa, A.; Jané-Valbuena, J.; Mapa, F. A.;
Thibault, J.; Bric-Furlong, E.; Raman, P.; Shipway, A.; Engels, I. H.; Cheng, J.; Yu, G. K.;
Yu, J.; Aspesi, P., Jr.; de Silva, M.; Jagtap, K.; Jones, M. D.; Wang, L.; Hatton, C.; Palescandolo, E.; Gupta, S.; Mahan, S.; Sougnez, C.; Onofrio, R. C.; Liefeld, T.;
MacConaill, L.;
Winckler, W.; Reich, M.; Li, N.; Mesirov, J. P.; Gabriel, S. B.; Getz, G.; Ardlie, K.; Chan,
V.; Myer, V. E.; Weber, B. L.; Porter, J.; Warmuth, M.; Finan, P.; Harris, J. L.; Meyerson,
M.; Golub, T. R.; Morrissey, M. P.; Sellers, W. R.; Schlegel, R.; Garraway, L. A., The Cancer
Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature
2012, 483 (7391), 603-607.
3. Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.;
Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.;
Milano, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S.
R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi,
H.; Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.;
Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J. W.; Baselga, J.; Stamenkovic, I.; Engelman, J.
A.; Sharma, S. V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.;
Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; McDermott, U.;
Benes, C. H., Systematic identification of genomic markers of drug sensitivity in cancer
cells. Nature 2012, 483 (7391), 570-575.
4. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.;
Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al., Feasibility of a high-flux anticancer drug
screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991,
83 (11), 757-66.
5. US Department of Health and Human Services Office of Minority Health Cancer and
African Americans. https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=16.
6. Lisovicz, N.; Wynn, T.; Fouad, M.; Partridge, E. E., Cancer health disparities: what we
have done. Am J Med Sci 2008, 335 (4), 254-259.
7. Badal, S.; Aiken, W.; Morrison, B.; Valentine, H.; Bryan, S.; Gachii, A.; Ragin, C., Disparities in prostate cancer incidence and mortality rates:
Solvable or not? The Prostate 2020,
80 (1), 3-16.
8. Toles, C. A., Black men are dying from prostate cancer. Abnf j 2008, 19 (3), 92-5.
9. Badal, S.; Campbell, K. S.; Valentine, H.; Ragin, C., The need for cell lines from diverse
ethnic backgrounds for prostate cancer research. Nature Reviews Urology 2019, 16 (12),
691-692.
10. Tannock, I. F.; de Wit, R.; Berry, W. R.; Horti, J.; Pluzanska, A.; Chi, K. N.; Oudard, S.;
Théodore, C.; James, N. D.; Turesson, I.; Rosenthal, M. A.; Eisenberger, M. A., Docetaxel
plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med 2004, 351 (15), 1502-12.
11. de Bono, J. S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J. P.; Kocak, I.; Gravis,
G.; Bodrogi, I.; Mackenzie, M. J.; Shen, L.; Roessner, M.; Gupta, S.; Sartor, A. O., Prednisone plus cabazitaxel
or mitoxantrone for metastatic castration-resistant prostate
cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet
2010, 376 (9747), 1147-54.
12. Prakash, O.; Hossain, F.; Danos, D.; Lassak, A.; Scribner, R.; Miele, L., Racial Disparities
in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic
Factors. Front Public Health 2020, 8, 576964-576964.
13. DeSantis, C. E.; Fedewa, S. A.; Goding Sauer, A.; Kramer, J. L.; Smith, R. A.; Jemal, A.,
Breast cancer statistics, 2015: Convergence of incidence rates between black and white
women. CA Cancer J Clin 2016, 66 (1), 31-42.
14. Clarke, S.; Chin, S.; Dodds, L.; George, S.; Badal, S., Racial Disparities in Breast Cancer
Treatment: From Pre-clinical to Clinical. Submitted to Breast Cancer Research 2021,
Unpublished.
15. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer Statistics, 2017. CA Cancer J Clin 2017, 67
(1), 7-30.
16. Blom, E. F.; Ten Haaf, K.; Arenberg, D. A.; de Koning, H. J., Disparities in Receiving
Guideline-Concordant Treatment for Lung Cancer in the United States. Ann Am Thorac
Soc 2020, 17 (2), 186-194.
17. Williams, C. D.; Alpert, N.; Redding, T. S. t.; Bullard, A. J.; Flores, R. M.; Kelley, M. J.; Taioli, E., Racial Differences in Treatment
and Survival among Veterans and Non-Veterans
with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations.
Cancer Epidemiol Biomarkers Prev 2020, 29 (1), 112-118.
18. Blackman, E.; Ashing, K.; Gibbs, D.; Kuo, Y. M.; Andrews, A.; Ramakodi, M.; Devarajan,
K.; Bucci, J.; Jean-Louis, G.; Richards-Waritay, O.; Wilson, B.; Bowen, C.; Edi, E.; Tolbert, V.;
Noumbissi, R.; Cabral, D. N.; Oliver, J.; Roberts, R.; Tulloch-Reid, M.; Ragin, C.,
The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity
among the African diaspora. Ethn Health 2021, 26 (5), 659-675.
19. Kim, E. S.; Tang, X.; Peterson, D. R.; Kilari, D.; Chow, C. W.; Fujimoto, J.; Kalhor,
N.; Swisher, S. G.; Stewart, D. J.; Wistuba, II; Siddik, Z. H., Copper transporter CTR1
expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer
2014, 85 (1), 88-93.
References